SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hoagland RJ. Infectious mononucleosis. Prim Care 1975; 2: 295307.
  • 2
    Devereaux CE, Bemiller T, Brann O. Ascites and severe hepatitis complicating Epstein-Barr infection. Am J Gastroenterol 1999; 94: 23640.
    Direct Link:
  • 3
    Auwaerter PG. Infectious mononucleosis in middle age. JAMA 1999; 281: 4549.
  • 4
    Cohen JI, Corey GR. Cytomegalovirus infection in the normal host. Medicine (Baltimore) 1985; 64: 10014.
  • 5
    Van Spronsen DJ, Breed WP. Cytomegalovirus-induced thrombocytopenia and hemolysis in an immunocompetent adult. Br J Haematol 1996; 92: 21820.
  • 6
    Remington JS. Toxoplasmosis in the adult. Bull N Y Acad Med 1974; 50: 21127.
  • 7
    Niu MT, Stein DS, Schnittman SM. Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in humans and animal retrovirus infections. J Infect Dis 1993; 168: 1490501.
  • 8
    Salar A, Juanpere N, Bellosillo B, Domingo-Domenech E, Espinet B, Seoane A, et al. Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study. Am J Surg Pathol 2006; 30: 127480.
  • 9
    Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 278095.
  • 10
    Evans RS, Takahashi K, Duane RT, Payne R, Liu C. Primary thrombocytopenic purpura and acquired hemolytic anemia: evidence for a common etiology. Arch Intern Med 1951; 87: 4865.
  • 11
    Rizvi MA, Evens AM, Tallman MS, Nelson BP, Rosen ST. T-cell non-Hodgkin lymphoma. Blood 2006; 107: 125564.
  • 12
    Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 1998; 128: 65762.
  • 13
    Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992; 19: 42430.
  • 14
    Sneller MC, Wang J, Dale JK, Strober W, Middelton LA, Choi Y, et al. Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood 1997; 89: 13418.
  • 15
    Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995; 268: 13479.
  • 16
    Rao VK, Oliveira JB. How I treat autoimmune lymphoproliferative syndrome. Blood 2011; 118: 574151.
  • 17
    Siegel RM, Chan FK, Chun HJ, Lenardo MJ. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immun 2000; 1: 46974.
  • 18
    Anand A, Dean G, Querishi K, Isenberg D, Lydyard P. Characterisation of CD3, CD47, CD87 (double negative) T cells in patients with systemic lupus erythematosus (SLE). Lupus 2002; 11: 493500.
  • 19
    Sneller MC, Dale JK, Straus SE. Autoimmune lymphoproliferative syndrome. Curr Opin Rheumatol 2003; 15: 41721.
  • 20
    Pensati L, Costanzo A, Ianni A, Accapezzato D, Iorio R, Natoli G, et al. Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis. Gastroenterology 1997; 113: 13849.
  • 21
    Kanegane H, Vilela MM, Wang Y, Futatani T, Matsukura H, Miyawaki T. Autoimmune lymphoproliferative syndrome presenting with glomerulonephritis. Pediatr Nephrol 2003; 18: 4546.
  • 22
    Perkins KD, Davis J, Price S, Uzel G, Su H, Aldridge P, et al. Extra-nodal manifestations of ALPS and related disorders: infiltrative pulmonary lesions [abstract]. Pediatr Blood Cancer 2011; 56: 9067.
  • 23
    Straus SE, Jaffe ES, Puck JM, Dale JK, Elkon KB, Rosen-Wolff A, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 2001; 98: 194200.
  • 24
    Holzelova E, Vonarbourg C, Stolzenberg MC, Arkwright PD, Selz F, Prieur AM, et al. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N Engl J Med 2004; 351: 140918.
  • 25
    Magerus-Chatinet A, Neven B, Stolzenberg MC, Daussy C, Arkwright PD, Lanzarotti N, et al. Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation. J Clin Invest 2011; 121: 10612.
  • 26
    Bi LL, Pan G, Atkinson TP, Zheng L, Dale JK, Makris C, et al. Dominant inhibition of Fas ligand-mediated apoptosis due to a heterozygous mutation associated with autoimmune lymphoproliferative syndrome (ALPS) type Ib. BMC Med Genet 2007; 8: 4155.
  • 27
    Zhu S, Hsu AP, Vacek MM, Zheng L, Schaffer AA, Dale JK, et al. Genetic alterations in caspase-10 may be causative or protective in autoimmune lymphoproliferative syndrome. Hum Genet 2006; 119: 28494.
  • 28
    Oliveira JB, Bleesing JJ, Dianzani U, Fleisher TA, Jaffe ES, Lenardo MJ, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood 2010; 116: e3540.
  • 29
    Desai NK, Morkhandikar S, Bajpai S, Pazare AR. Autoimmune lymphoproliferative disorder in an adult patient. J Postgrad Med 2011; 57: 1313.
  • 30
    Vaishnaw AK, Orlinick JR, Chu JL, Krammer PH, Chao MV, Elkon KB. The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. J Clin Invest 1999; 103: 35563.
  • 31
    Chavele KM, Ehrenstein MR. Regulatory T-cells in systemic lupus erythematosus and rheumatoid arthritis. FEBS Lett 2011; 585: 360310.